Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis

Abstract

Patients with diabetes mellitus are at increased risk of developing atherosclerotic disease. The extent of this additional risk and its determinants are not well known, but this information is needed for sample-size estimations in intervention studies. Therefore, a meta-analysis of epidemiologic studies on this subject was performed. Medline was searched from 1966 onwards, including the reference lists of all relevant publications. A total of 27 prospective follow-up studies in the English language that allowed calculation of the unadjusted incidence of one of the predefined outcome events were included. The influence of age, sex, type of diabetes, duration of diabetes, year of study, HbA_1c, cholesterol level, blood pressure and smoking on these incidences was studied by means of univariate Poisson regression analysis.

Overall total mortality was 2.9% per year (95% CI 2.8-3.0; 27 studies), and for death from all vascular causes was 1.4% per year (95% CI 1.3-1.4; 16 studies). Only two studies were found that reported on the incidence of the composite outcome `event death from all vascular causes, non-fatal myocardial infarction, or non-fatal stroke'. In univariate analysis, age, year of study, total cholesterol and systolic blood pressure were positively related to total mortality and death from all vascular causes. After adjustment for age, or limiting the analyses to studies in patients with type 2 diabetes only (n = 11), these relationships remained statistically significant. In conclusion, the overall yearly total mortality in diabetes mellitus is 2.9% and for death from all vascular causes is 1.4%. There are few data on the incidence of composite cardiovascular outcome events.

Keywords

cardiovascular disease determinants diabetes incidence mortality

References

Donahue RP , Orchard TJ. Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care 1992; 15: 1141-1155.

Jarrett RJ. Epidemiology and public health aspects of non-insulin-dependent diabetes mellitus. Epidemiol Rev 1989; 11: 151-171.

Turner R , Cull C , Holman R. United Kingdom prospective diabetes study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-depen-dent diabetes mellitus. Ann Intern Med 1996; 124: 136-145.

Keech A , Collins R , MacMahon S et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-269.

Collins R , Peto R , MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.

Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.

Vandenbroucke JP. A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio. Am J Epidemiol 1982; 115: 303-304.

Borch Johnsen K , Andersen PK , Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 590-596.

Pell S , D’Alonzo CA. Factors associated with long-term survival of diabetics. JAMA 1970; 214: 1833-1840.

10.

Herman JB , Medalie JH , Goldbourt U. Differences in cardiovascular morbidity and mortality between previously known and newly diagnosed adult diabetics. Diabetologia 1977; 13: 229-234.

11.

Jarrett RJ , McCartney P , Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79-84.

12.

Shenfield GM , Elton RA , Bhalla IP , Duncan LJ. Diabetic mortality in Edinburgh. Diabetes Metab 1979; 5: 149-158.

13.

Reunanen A : Mortality in type 2 diabetes. Ann Clin Res 1983; 15 (suppl 37): 26-28.

14.

Sasaki A , Horiuchi N , Hasegawa K , Uehara M. Mortality from coronary heart disease and cerebrovascular disease and associated risk factors in diabetic patients in Osaka District, Japan. Diabetes Res Clin Pract 1995; 27: 77-83.

15.

Jarrett RJ , Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease—putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988; 31: 737-740.

16.

Kleinman JC , Donahue RP , Harris MI , Finucane FF , Madans JH , Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128: 389-401.

17.

Barrett Connor E , Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol 1983; 118: 489-496.

18.

De Grauw WJC , van de Lisdonk EH , van den Hoogen HJM , van Weel C. Cardiovascular morbidity and mortality in type 2 diabetic patients: a 22-year historical cohort study in Dutch general practice. Diabet Med 1995; 12: 117-122.

19.

Nelson RG , Sievers ML , Knowler WC et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 1990; 81: 987-995.

20.

Rosengren A , Welin L , Tsipogianni A , Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989; 299: 1127-1131.

21.

Manson JE , Colditz GA , Stampfer MJ et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1147.

22.

Andersson DKG , Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995; 18: 1534-1543.

23.

Stamler JS , Vaccaro O , Neaton JD , Wentworth D. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.

24.

Stephenson JM , Kenny S , Stevens LK , Fuller JH , Lee E , and the WHO Multinational Study Group . Proteinuria and mortality in diabetes: the WHO multinational study of vascular diseases in diabetes. Diabet Med 1995; 12: 149-155.

25.

Uusitupa MI , Niskanen LK , Siitonen O , Voutilainen E , Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36: 1175-1184.

26.

Neil A , Hawkins M , Potok M , Thorogood M , Cohen D , Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16: 996-1003.

27.

Walters DP , Gatling W , Houston AC , Mullee MA , Julious SA , Hill RD. Mortality in diabetic subjects: an eleven-year follow-up of a community-based population. Diabet Med 1994; 11: 968-973.

28.

Lehto S , Niskanen L , Suhonen M , Rönnemaa T , Laakso M. Medial artery calcification - a neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978-983.

29.

Waugh NR , Dallas JH , Jung RT , Newton RW. Mortality in a cohort of diabetic patients; causes and relative risks. Diabetologia 1989; 32: 103-104.

30.

Hanis CL , Chu HH , Lawson K , Hewett-Emmett D , Barton SA , Schull WJ , Garcia CA. Mortality of Mexican Americans with NIDDM: retinopathy and other predictors in Starr County, Texas. Diabetes Care 1993; 16: 82-89.

31.

Araki S , Kikkawa R , Haneda M et al. Microalbuminuria cannot predict cardiovascular death in Japanese subjects with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1995; 9: 323-325.

32.

Damsgaard EM , Froland A , Jorgensen OD , Mogensen CE. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992; 41: 731-735.

33.

Rossing P , Hougaard P , Borch-Johnsen K , Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996; 313: 779-784.

34.

Gall MA , Borch-Johnsen K , Hougaard P , Nielsen FS , Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-1309.

35.

Sasaki A , Uehara M , Horiuchi N , Hasagawa K. A long-term follow-up study of Japanese diabetic patients: mortality and causes of death. Diabetologia 1983; 25: 309-312.

36.

Head J , Fuller JH. International variations in mortality among diabetic patients: the WHO Multinational Study of Vascular disease in diabetics. Diabetologia 1990; 33: 477-481.

37.

Uusitupa MI , Niskanen LK , Siitonen O , Voutilainen E , Pyorala K. 5- year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990; 82: 27-36.

38.

Janzon L , Bergqvist D , Boberg M et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish ticlopidine multi-centre study. J Intern Med 1990; 227: 301-308.

39.

Balsano F , Violi F , and ADEP Group . Effect of picotamide on clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation 1993; 87: 1563-1569.

40.

Steering Committee of the Physicians’ Health Study Research Group . Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 321: 129-135.

41.

Peto R , Gray R , Collins R et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-316.

42.

Antiplatelet Trialists’ Collaboration . Collaborative overview of randomised trials of antiplatelet therapy -I: Prevention of death, myocar-dial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.

43.

Karlson BW , Herlitz J , Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med 1993; 10: 449-454.

44.

O’Sullivan JJ , Conroy RM , Robinson K , Hickey N , Mulcahy R. Inhospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care 1991; 14: 758-760.

45.

Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123-131.

46.

Feskens EJ , Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol 1992; 45: 1327-1334.

47.

Stamler J , Vaccaro O , Neaton JD , Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.

48.

Turner RC , Millns H , Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998; 316: 823-828.

49.

Pyörälä K , Pedersen TR , Kjekhus J , Faergeman O , Olsson AG , Thorgeirsson G , for the Scandinavian Simvastatin Survival Study (4S) Group . Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-620.

50.

Sacks FM , Pfeffer MA , Lemuel AM et al for the Cholesterol and Recurrent Events Trial Investigators . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.

51.

UK Prospective Diabetes Study Group . Tight blood pressure control and the risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-713.

52.

UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.